Novo Nordisk's pricing strategies within the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of cost gouging, stating the stark contrast between U.S. charges and those in Europe and copyright.California biotech behemoth Amgen ditched options for an experimental weight loss tablet in May possibly but